BioAffinity appoints Michael Dougherty as CFO; former CFO Edwards resigns

bioAffinity Technologies, Inc.

Michael Edwards resigned as CFO effective May 1; will serve as consultant for transition.
Michael Dougherty appointed CFO; previously CFO of Alexa Business Domains at Amazon.
Dougherty receives $250K base salary, $30K cash signing bonus, plus $100K restricted stock grant.
Dougherty brings 20+ years finance experience; will support commercial rollout of CyPath® Lung.
Company is a biotech focused on noninvasive early-stage cancer detection.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Dougherty

Vice President and Chief Financial Officer

BIAF · bioAffinity Technologies, Inc.

Effective: 2023-05-01
Filed: May 1, 2023, 7:59 PM ET

Effective May 1, 2023, the Company appointed Michael Dougherty (age 44) to serve as the Company’s new Vice President and Chief Financial Officer (principal financial officer and principal accounting officer).

Departed

Michael Edwards

Chief Financial Officer

BIAF · bioAffinity Technologies, Inc.

Effective: 2023-05-01
Successor: Michael Dougherty
Filed: May 1, 2023, 7:59 PM ET

Effective May 1, 2023, Michael Edwards, the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), resigned.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Dougherty was appointed as Vice President and Chief Financial Officer at bioAffinity Technologies, Inc..

Action: appointed
Role: Vice President and Chief Financial Officer

Exact text from the filing

Effective May 1, 2023, the Company appointed Michael Dougherty (age 44) to serve as the Company’s new Vice President and Chief Financial Officer (principal financial officer and principal accounting officer).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Edwards resigned as Chief Financial Officer at bioAffinity Technologies, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Effective May 1, 2023, Michael Edwards, the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), resigned.

View on SEC.gov

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-014937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.